Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Full text
Author(s):
Gimenez, Alba Marina [1, 2] ; Salman, Ahmed M. [2] ; Marques, Rodolfo F. [1] ; Lopez-Camacho, Cesar [2] ; Harrison, Kate [2] ; Kim, Young Chan [2] ; Janse, Chris J. [3] ; Soares, Irene S. [1] ; Reyes-Sandoval, Arturo [2, 4]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, SP - Brazil
[2] Univ Oxford, Jenner Inst, Nuffield Dept Med, Henry Wellcome Bldg Mol Physiol, Roosevelt Dr, Oxford OX3 7BN - England
[3] Leiden Univ Med Ctr, Dept Parasitol, Leiden Malaria Res Grp, Ctr Infect Dis, L4-Q, Albinusdreef 2, NL-2333 ZA Leiden - Netherlands
[4] Inst Politecnico Nacl, Unidad Adolfo Lopez Mateos, Ave Luis Enrique Erro S-N, Mexico City 07738, DF - Mexico
Total Affiliations: 4
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 11, n. 1 SEP 9 2021.
Web of Science Citations: 0
Abstract

Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of PvCSP (VK210, VK247 and P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic P. berghei parasites expressing PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each PvCSP allelic variant. Immunized mice were challenged with two existing chimeric P. berghei parasite lines expressing PvCSP-VK210 and PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant, PvCSP-P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of P. vivax. (AU)

FAPESP's process: 12/13032-5 - Generation and analysis of the immunogenicity of recombinant proteins based on the different allelic forms of the circumsporozoite antigen of Plasmodium vivax aiming at the development of a universal vaccine against malaria
Grantee:Irene da Silva Soares
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 16/26123-0 - Analysis of protective immunity of vaccine formulations against Plasmodium vixax after challenge with P. berghei/P. vivax transgenic parasites in murine model
Grantee:Alba Marina Gimenez
Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
FAPESP's process: 14/18102-7 - Preclinical tests of recombinant adenovirus-based protein and vaccine formulations expressing the Plasmodium vivax circumsporozoite protein
Grantee:Alba Marina Gimenez
Support Opportunities: Scholarships in Brazil - Post-Doctorate